[go: up one dir, main page]

ZA200409814B - 3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition. - Google Patents

3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition.

Info

Publication number
ZA200409814B
ZA200409814B ZA200409814A ZA200409814A ZA200409814B ZA 200409814 B ZA200409814 B ZA 200409814B ZA 200409814 A ZA200409814 A ZA 200409814A ZA 200409814 A ZA200409814 A ZA 200409814A ZA 200409814 B ZA200409814 B ZA 200409814B
Authority
ZA
South Africa
Prior art keywords
methyl
methylcarbnonyl
monoethanesulphonate
indolinone
anilino
Prior art date
Application number
ZA200409814A
Other languages
English (en)
Inventor
Gerald Juergen Roth
Peter Sieger
Guenter Linz
Werner Rall
Frank Hilberg
Thomas Bock
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200409814(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ZA200409814B publication Critical patent/ZA200409814B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA200409814A 2002-07-24 2004-12-03 3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition. ZA200409814B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ZA200409814B true ZA200409814B (en) 2006-02-22

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200409814A ZA200409814B (en) 2002-07-24 2004-12-03 3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition.

Country Status (35)

Country Link
US (2) US7119093B2 (es)
EP (2) EP2386543A1 (es)
JP (1) JP5039279B2 (es)
KR (1) KR101145691B1 (es)
CN (1) CN100351235C (es)
AR (2) AR040662A1 (es)
AT (1) ATE551322T1 (es)
AU (1) AU2003254376B2 (es)
BR (1) BRPI0312811B8 (es)
CA (1) CA2493310C (es)
CY (1) CY1112916T1 (es)
DE (1) DE10233500A1 (es)
DK (1) DK1527047T3 (es)
EA (1) EA008684B1 (es)
EC (1) ECSP055571A (es)
EG (1) EG24562A (es)
ES (1) ES2384968T3 (es)
HR (1) HRP20050070B1 (es)
IL (2) IL166405A0 (es)
ME (1) ME00353B (es)
MX (1) MXPA04012785A (es)
MY (1) MY136883A (es)
NO (1) NO330486B1 (es)
NZ (1) NZ538367A (es)
PE (1) PE20040704A1 (es)
PL (1) PL223758B1 (es)
PT (1) PT1527047E (es)
RS (1) RS52283B (es)
SA (1) SA03240446B1 (es)
SI (1) SI1527047T1 (es)
TW (1) TWI285635B (es)
UA (1) UA78352C2 (es)
UY (1) UY27904A1 (es)
WO (1) WO2004013099A1 (es)
ZA (1) ZA200409814B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
AU2008265104B2 (en) 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
RU2525114C2 (ru) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
PL2299987T3 (pl) * 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
DK2985025T3 (en) 2008-06-06 2018-03-19 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429527A1 (en) * 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of cancer and fibrotic diseases
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
WO2017178428A1 (en) 2016-04-13 2017-10-19 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
WO2017198202A1 (zh) * 2016-05-19 2017-11-23 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
JP2019522638A (ja) 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
US10772885B2 (en) 2016-09-26 2020-09-15 Reyoung (Suzhou) Biology Science & Technology Co., Ltd. Composition for treating ocular diseases and methods of usage and making
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
US10981896B2 (en) * 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
WO2018165865A1 (zh) * 2017-03-14 2018-09-20 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
JP2020512364A (ja) 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited Process for the preparation of nintedanib
FI3700529T3 (fi) 2017-10-23 2025-09-18 Boehringer Ingelheim Int Uusi aktiivisten aineiden yhdistelmä etenevien fibrotisoivien interstitiaalisten keuhkosairauksien (pf-ild) hoitoon
US11261158B2 (en) 2017-11-17 2022-03-01 Fermion Oy Synthesis of 2-indolinone derivatives
CA3093225A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
WO2020041631A1 (en) 2018-08-22 2020-02-27 Avalyn Pharma Inc. Specially formulated compositions of inhaled nintedanib and nintedanib salts
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
WO2021236935A1 (en) 2020-05-22 2021-11-25 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
WO2022029805A1 (en) * 2020-08-07 2022-02-10 Bdr Lifesciences Private Limited An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN119630395A (zh) 2022-02-28 2025-03-14 努福米克斯技术有限公司 用于治疗特发性肺纤维化的组合物和方法
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en) 2023-12-27 2025-07-02 Faran S.A. Oral suspensions comprising nintedanib esylate
KR20250118711A (ko) 2024-01-30 2025-08-06 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 생체이용률이 개선된 경구투여용 제제
WO2025261988A1 (fr) 2024-06-17 2025-12-26 Assistance Publique Hopitaux De Paris Utilisation de nintédanib pour le traitement de la maladie de castleman

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
BR0013498A (pt) * 1999-08-23 2002-05-14 Solvay Pharm Bv Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CY1112916T1 (el) 2016-04-13
AU2003254376A1 (en) 2004-02-23
CA2493310C (en) 2011-01-18
PE20040704A1 (es) 2004-11-29
HRP20050070B1 (hr) 2013-09-30
IL166405A0 (en) 2006-01-15
NZ538367A (en) 2008-01-31
EA200500146A1 (ru) 2005-08-25
EP1527047B1 (en) 2012-03-28
ME00353B (me) 2011-10-10
PT1527047E (pt) 2012-06-28
HRP20050070A2 (en) 2005-12-31
DK1527047T3 (da) 2012-07-16
CN1671660A (zh) 2005-09-21
BR0312811A (pt) 2005-04-19
TW200409754A (en) 2004-06-16
CN100351235C (zh) 2007-11-28
SA03240446B1 (ar) 2007-07-31
AR094217A2 (es) 2015-07-15
KR20050042139A (ko) 2005-05-04
US20060258681A1 (en) 2006-11-16
TWI285635B (en) 2007-08-21
AU2003254376B2 (en) 2010-06-17
RS20050046A (sr) 2007-09-21
US20040176392A1 (en) 2004-09-09
AR040662A1 (es) 2005-04-13
KR101145691B1 (ko) 2012-05-25
ES2384968T3 (es) 2012-07-16
ECSP055571A (es) 2005-04-18
BRPI0312811B8 (pt) 2021-05-25
NO20050985L (no) 2005-02-23
RS52283B (sr) 2012-10-31
SI1527047T1 (sl) 2012-07-31
NO330486B1 (no) 2011-04-26
BRPI0312811B1 (pt) 2019-03-12
BRPI0312811A8 (pt) 2019-01-02
UY27904A1 (es) 2004-02-27
HK1078851A1 (zh) 2006-03-24
UA78352C2 (uk) 2007-03-15
MEP53708A (en) 2011-05-10
EP2386543A1 (en) 2011-11-16
PL372996A1 (en) 2005-08-08
WO2004013099A1 (en) 2004-02-12
EP1527047A1 (en) 2005-05-04
ATE551322T1 (de) 2012-04-15
CA2493310A1 (en) 2004-02-12
US7119093B2 (en) 2006-10-10
EG24562A (en) 2009-10-25
PL223758B1 (pl) 2016-10-31
MXPA04012785A (es) 2005-06-08
EA008684B1 (ru) 2007-06-29
IL166405A (en) 2009-11-18
JP2005535684A (ja) 2005-11-24
MY136883A (en) 2008-11-28
DE10233500A1 (de) 2004-02-19
JP5039279B2 (ja) 2012-10-03

Similar Documents

Publication Publication Date Title
ZA200409814B (en) 3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition.
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
IL163158A (en) 4-(4-methyl- piperazin -1- ylmethyl)- benzamide derivatives
SI1572708T1 (sl) Novi heterociklicni fluoroglikozidni derivati, zdravila, ki vsebujejo te spojine, in njihova uporaba
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
EP1587474A3 (en) Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
PL375789A1 (en) Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
IL164455A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
EP1571146A4 (en) NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
IL164987A (en) Proline derivatives and pharmaceutical compositions containing the same
IL157029A0 (en) Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL191960A0 (en) Heterocyclic aromatic compounds and pharmaceutical compositions containing the same
IL166129A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL166512A0 (en) Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
IL169112A (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
GB0225676D0 (en) New use for pharmaceutical composition
AP2005003251A0 (en) New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors.
IL164032A0 (en) 5-ä2-Hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropyl-propionylaminoü-phtalide and related compounds with progesteronepeceptor
PL372724A1 (en) (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SI1558595T1 (sl) Piperazinilni in diazapanilni benzamidi in benztioamidi
IL165389A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
IL181191A0 (en) Piperazine and piperidine derivatives and their use as chemokine receptor antagonists
IL181216A (en) 5, 3-SICO-4-NORKOLSTAN DERIVATIVES AND PHARMACEUTICAL COMPONENTS CONTAINING @ THEM